Edition:
United Kingdom

Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

189.80SEK
18 May 2018
Change (% chg)

0.80kr (+0.42%)
Prev Close
189.00kr
Open
190.00kr
Day's High
199.00kr
Day's Low
185.00kr
Volume
40,792
Avg. Vol
25,242
52-wk High
199.00kr
52-wk Low
75.50kr

Latest Key Developments (Source: Significant Developments)

Immunovia Approved For Listing On Nasdaq Stockholm
Monday, 26 Mar 2018 

March 26 (Reuters) - IMMUNOVIA AB (PUBL) ::IMMUNOVIA HAS BEEN APPROVED FOR LISTING ON NASDAQ STOCKHOLM.‍FIRST DAY OF TRADING ON NASDAQ STOCKHOLM IS SCHEDULED FOR 3 APRIL 2018​.‍LAST DAY OF TRADING ON NASDAQ FIRST NORTH IS SCHEDULED FOR 29 MARCH 2018​.  Full Article

Immunovia Q3 net loss widens to SEK 11.6 mln‍​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - IMMUNOVIA AB (PUBL) :NET SALES FOR Q3 2017 WERE SEK 27 THOUSAND (5 K)‍​.THE NET LOSS FOR Q3 2017 WAS SEK 11,589 THOUSAND (-4,048 K)‍​.  Full Article

Immunovia gets SEK 4.9 mln grant from Swelife Accelerator Innovation Program
Monday, 30 Oct 2017 

Oct 30 (Reuters) - IMMUNOVIA AB (PUBL) ::IMMUNOVIA RECEIVES SEK4.9 MILLION GRANT FROM SWELIFE ACCELERATOR INNOVATION PROGRAM.  Full Article

Immunovia starts cooperation with ‍Linköping University Medical Faculty ​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - IMMUNOVIA AB (PUBL) :STARTS COOPERATION WITH ‍LINKÖPING UNIVERSITY MEDICAL FACULTY ​.  Full Article

Immunovia holdig detailed talks about participation in large consortium
Monday, 5 Sep 2016 

Immunovia AB (publ) :Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer.  Full Article

Immunovia H1 operating loss widens to SEK 5.4 million
Wednesday, 24 Aug 2016 

Immunovia publ AB : H1 net sales 66,000 Swedish crowns ($7,870) versus 59,000 crowns year ago .H1 operating loss 5.4 million crowns versus loss 3.8 million crowns year ago.  Full Article

Immunovia intends to apply for listing on Nasdaq Stockholm's Main Market
Tuesday, 16 Aug 2016 

Immunovia publ AB :Announces intention to apply during H1 2017 for listing on Nasdaq Stockholm's Main Market.  Full Article

Immunovia: 96 pct of early stage pancreatic cancer patients detected
Monday, 30 May 2016 

Immunovia Publ AB :96 percent of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort.  Full Article

BRIEF-Immunovia AB (Publ) says AGM Resolved Chairman Of Board Should Be Compensated With Sek 400,000

* IMMUNOVIA AB (PUBL) AGM RESOLVED THAT BOARD MEMBERS SHOULD BE COMPENSATED WITH SEK 150,000 FOR DIRECTORS AND SEK 400,000 FOR CHAIRMAN OF BOARD Source text for Eikon: Further company coverage: